(Pancreatic Cancer) Is Sotorasib Monotherapy Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On December 21, 2022, John H. Strickler et al. from Duke Cancer Center published in the medical journal The New England Journal of Medicine the "Efficacy and Safety Results of Sotorasib Monotherapy in Pretreated Advanced Pancreatic Cancer Patients with KRAS G12C Gene Mutations, from the CodeBreaK 100 Phase 1/2 Clinical Trial."
The CodeBreaK 100 trial was a single-arm Phase 2 clinical trial that treated pretreated advanced pancreatic cancer patients with KRAS G12C mutations (N=38) with Sotorasib 960 mg once daily. The primary endpoint was the objective response rate.
The trial results showed a primary endpoint objective response rate of 21%, progression-free survival of 4.0 months, and median overall survival of 6.9 months.
In terms of safety, the adverse event incidence rate was 42% (N=16), with Grade 3 or higher adverse events occurring in 16% of patients. No patient deaths due to adverse events were confirmed.
Based on the CodeBreaK 100 trial results, John H. Strickler et al. stated: "In pretreated advanced pancreatic cancer patients with KRAS G12C gene mutations, Sotorasib monotherapy demonstrated good antitumor activity with a favorable safety profile."
Source: https://oncolo.jp/news/230120y01
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4